Major Areas of Research
- Persistence of viral reservoirs in HIV-infected individuals receiving antiretroviral therapy.
- Viral dynamics and immunologic control of HIV replication in infected individuals.
- Development of therapeutic strategies aimed at achieving sustained virologic control in HIV-infected individuals in the absence of antiretroviral therapy.
Our research program focuses on 1) delineating the role of viral reservoirs in the pathogenesis of HIV disease; 2) examining host and viral factors that contribute to the maintenance of HIV reservoirs; and 3) developing therapeutic strategies aimed at achieving durable virologic control in infected individuals in the absence of antiretroviral therapy. Our research program utilizes Bench-to-Bedside approaches. We conduct comprehensive genetic, immunologic, and virologic analyses of CD4+ and CD8+ T cells in diverse cohorts of HIV-infected individuals in order to address fundamental pathogenic questions, such as elucidating mechanisms of viral persistence, the role of the host immunity in containment of viral replication and evaluating promising novel therapeutic agents in both ex vivo and in vivo settings. Based on findings from bench research, we also conduct phase I clinical trials in close collaboration with the NIAID HIV clinic, with the ultimate goal of developing safe, effective, and scalable therapeutic strategies that would allow HIV-infected individuals to control viral replication in the absence of daily antiretroviral drugs.
Dr. Chun received his Ph.D. from the Biochemistry, Cellular, and Molecular Biology Graduate Program from the Johns Hopkins University School of Medicine where he discovered and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. He began his postdoctoral work in the Laboratory of Immunoregulation at NIAID as a research fellow in 1997. Subsequently, Dr. Chun was appointed to the position of staff scientist in 2001. Dr. Chun was selected as one of the Earl Stadtman Investigators and received a tenure track investigator position in the LIR in June 2016.
Members of the HIV Immunovirology Unit Research Group
- Jana Blazkova, Ph.D., staff scientist
- Katherine E. Clarridge, M.D., special volunteer
- Erin D. Huiting, postbaccalaureate fellow, Intramural Research Training Awards Program
- J. Shawn Justement, senior research assistant
- Victoria Shi, M.S., biologist
Kardava L, Sohn H, Youn C, Austin JW, Wang W, Buckner CM, Justement JS, Melson VA, Roth GE, Hand MA, Gittens KR, Kwan RW, Sneller MC, Li Y, Chun TW, Sun PD, Pierce SK, Moir S. IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol. 2018 Sep;19(9):1001-1012.
Clarridge KE, Blazkova J, Einkauf K, Petrone ME, Refsland EW, Sneller MC, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 2017;13:e1006792.
Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, Kwan R, Shi V, Blazkova J, Refsland EW, Morris DE, Cohen KW, McElrath MJ, Xu R, Egan MA, Eldridge JH, Benko E, Kovacs C, Moir S, Chun TW, Fauci AS. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017 Dec 6;9(419).
Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017 Mar 23;543:559-63.
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O’Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P and Chun T-W. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Eng J Med. 2016 Nov;375(21):2037-50.
Therapeutic Vaccine for HIV, NCT01859325